Alkyl Amines has registered 172 percent jump in its Q3 consolidated net profit at Rs 60.4 crore versus Rs 22.2 crore, YoY.
Promoter Chandrakant Rathi Innovations and Projects Pvt Ltd sold another 2.20 percent stake in the company on March 11
Atharva Green Ecotech LLP also sold its entire 6.24 percent stake through open market transaction on March 8.
Post the Q1 results, the management has maintained its guidance for a topline of Rs 440-450 crores along with an operational profit of 190-200 crore. We believe there could be some upside risks (3-5%) to this guidance on account of the rupee depreciation.
Avenue Supermarts, the operator of supermarket retail chain D-Mart on Tuesday, more than doubled investors’ wealth on debut itself.
Axis Direct is bullish on Advanced Enzyme Technologies has recommended buy rating on the stock with a target price of Rs 1850 in its research report dated February 21, 2017.
According to Technical Analyst, Prakash Gaba, support for Nifty at 7897 and resistant at 8100.
Havells India, M&M Financial Services, Petronet LNG, Piramal Enterprises and UPL are among the six companies to be added to the MSCI India domestic index.
More than 70 percent of the newly-listed companies are trading well above their issue price, giving handsome returns of up to 98 percent.
On September 2, 2016 Kotak India Venture Fund I sold 5,17,200 shares of Advanced Enzyme Technologies.
Tata Motors | HCL Technologies | Ambuja Cements | Wipro | Sun Pharma | ONGC | Torrent Power | WIM Plast | EIH | HEG | UFO Moviez | Ugar Sugar | Godrej Consumer | Insecticides India | Uttam Value Steels | Century Plyboard and L&T Infotech are stocks, which are in the news today.
The issue was priced at Rs 880-896 per share, which raised over Rs 411 crore through its initial public offering. Retail investors category was oversubscribed 11.6 times.
Advanced Enzyme Technologies is listed at Rs 1210 per share, up 35 percent from issue price of Rs 896 per share. Price band of the issue, which raised over Rs.411 crore through its initial public offering IPO, was subscribed 116 times at a price band of Rs.880-896 per share.
After an overwhelming response from investors to the issue that oversubscribed nearly 116 times, shares are expected to debut with hefty premium over its issue price as currently the grey market premium is more than Rs 300, say dealers.
The Rs 411.5-crore initial public offer of Advanced Enzyme Technologies was oversubscribed 4.28 times on the second day of the offer today.
The Rs 411.5-crore IPO received bids for 41,13,648 shares against the total issue size of 32,34,059 shares, data available with the NSE till 1030 hrs showed.
The Rs 411.5-crore IPO received bids for 28,90,304 shares against the total issue size of 32,34,059, data available with the NSE till 1700 hours showed.
Most analysts seem to be impressed with the IPO and recommend subscribing it. The proceeds of the fresh issue will be used towards repayment/pre-payment of certain loans availed by Advanced Enzymes USA and general corporate purposes.
Little over 13.71 lakh shares were allotted to the anchor investors at Rs 896 apiece, the upper end of the price band for the Rs 411 crore IPO.
The IPO comprises fresh issue of equity shares worth Rs 50 crore and an offer for sale (OFS) for up to 4,034,470 scrips by promoter group shareholders, along with Kotak Employees Investment Trust, Kotak India Venture Fund I and Kotak India Venture (Offshore) Fund.
The company is selling equity shares with face value of Rs 10 each at a price of Rs 880-896 aggregating to Rs 50 crore and an offer for sale by promoter group shareholders, along with Kotak Employees Investment Trust, Kotak India Venture Fund I and Kotak India Venture (Offshore) Fund.